₹2,577.90
+1.04%NSE close, 16 Nov 2026
+7.39%
RPG Life Sciences is a small cap company, listed on NSE under the symbol RPGLIFE. At ₹2,577.90 a share, the market values the whole company at ₹4,264 crore.
In FY26, it reported sales of ₹708 crore and a net profit of ₹115 crore, an operating margin of 20.8%. Over the last three years, sales grew 17.1% a year and net profit grew 30.8% a year.
The market values the company at 39.0 times its profit over the last twelve months and 6.20 times its book value; its return on equity is 15.9% and it has almost no borrowings.
Promoters hold 72.95% of the shares. Foreign institutions hold 0.87%, and domestic institutions, mutual funds among them, 9.93%.
Over the past year the share price has risen 5.2%, and it is 17.6% below its 52-week high.
₹ crore. Consolidated figures where the company filed them, standalone otherwise (marked S).
| Line | Dec 2023 S | Mar 2024 S | Jun 2024 S | Sep 2024 S | Dec 2024 S | Mar 2025 S | Jun 2025 S | Sep 2025 S |
|---|
Transcript
Link of Recording
Amendment to Policy on Related Party Transactions
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 154 | 127 | 165 | 172 | 173 | 143 | 169 | 182 | 180 | 177 | 196 | 212 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 116 | 106 | 126 | 126 | 124 | 118 | 133 | 143 | 140 | 144 | 152 | 171 |
| Operating profit | 37.9 | 20.7 | 39.1 | 45.9 | 49.2 | 25.5 | 35.5 | 39.0 | 39.8 | 32.8 | 43.3 | 40.4 |
| Operating margin | 24.7% | 16.3% | 23.6% | 26.7% | 28.5% | 17.8% | 21.0% | 21.5% | 22.1% | 18.6% | 22.1% | 19.1% |
| Other income | 1.9 | 1.7 | 2.4 | 1.9 | 3.3 | 5.1 | 5.2 | 4.5 | 3.4 | 12.4 | 4.7 | 4.3 |
| Interest | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.3 | 0.4 | 0.6 | 0.8 |
| Depreciation | 4.1 | 4.5 | 5.3 | 5.3 | 5.5 | 5.4 | 5.1 | 5.2 | 5.4 | 5.7 | 5.9 | 6.8 |
| Profit before tax | 35.5 | 17.7 | 36.0 | 15.1 | 46.9 | 135 | 35.4 | 49.5 | 29.1 | 40.2 | 41.5 | 37.0 |
| Tax | 9.1 | 4.5 | 9.2 | 10.9 | 12.0 | 17.6 | 9.1 | 12.6 | 7.0 | 10.3 | 10.7 | 8.8 |
| Net profit | 26.5 | 13.2 | 26.8 | 4.2 | 34.9 | 117 | 26.3 | 36.9 | 22.1 | 29.9 | 30.8 | 26.6 |
| EPS (₹) | 16.00 | 8.01 | 16.18 | 2.54 | 21.12 | 70.96 | 15.90 | 22.28 | 13.38 | 18.08 | 18.60 | 17.07 |
₹ crore, financial years to March.
| Line | FY19 S | FY20 S | FY21 S | FY22 S | FY24 S | FY25 S | FY26 |
|---|---|---|---|---|---|---|---|
| Sales | 330 | 376 | 389 | 440 | 582 | 653 | 708 |
| Expenses | 297 | 316 | 319 | 354 | 454 | 494 | 560 |
| Operating profit | 33.6 | 59.2 | 69.9 | 86.4 | 128 | 160 | 147 |
| Operating margin | 10.2% | 15.7% | 18.0% | 19.6% | 22.0% | 24.4% | 20.8% |
| Other income | 0.8 | 0.7 | 0.9 | 3.0 | 7.2 | 12.7 | 25.6 |
| Interest | 4.0 | 1.8 | 0.8 | 0.5 | 0.5 | 0.6 | 0.9 |
| Depreciation | 15.3 | 16.4 | 16.5 | 15.7 | 17.1 | 21.4 | 21.5 |
| Profit before tax | 15.1 | 36.5 | 53.6 | 73.2 | 118 | 233 | 154 |
| Tax | 4.2 | 7.4 | 13.6 | 21.7 | 30.2 | 49.6 | 39.0 |
| Net profit | 10.8 | 29.0 | 40.0 | 51.5 | 87.7 | 183 | 115 |
| EPS (₹) | 6.54 | 17.54 | 24.19 | 31.13 | 53.01 | 110.80 | 18.08 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 64.8 | 77.9 | 56.5 | 10.5 |
| From investing | −34.7 | −41.8 | 85.8 | −257 |
| From financing | −13.5 | −27.1 | −20.6 | 207 |
| Spent on fixed assets | −24.0 | −36.0 | −65.4 | −33.3 |
| Free cash flow | 40.8 | 41.8 | −8.9 | −22.9 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net margin | 3.3% | 7.7% | 10.3% | 11.7% | 15.1% | 28.0% | 16.3% |
| Operating margin | 10.2% | 15.7% | 18.0% | 19.6% | 22.0% | 24.4% | 20.8% |
| Return on equity | – | – | – | – | 23.4% | 34.5% | 19.0% |
| Return on capital employed | – | – | – | – | 31.6% | 44.0% | 24.8% |
| Return on assets | – | – | – | – | 17.1% | 27.9% | 14.5% |
| Debt to equity | – | – | – | – | 0.00 | 0.00 | 0.03 |
| Interest coverage | 4.80 | 21.80 | 68.80 | 141.70 | 262.90 | 376.60 | 174.30 |
| Debt to assets | – | – | – | – | 0.00 | 0.00 | 0.03 |
| Current ratio | – | – | – | – | 2.29 | 3.90 | 3.52 |
| Quick ratio | – | – | – | – | 1.51 | 3.12 | 2.75 |
| Cash ratio | – | – | – | – | 0.15 | 0.24 | 0.94 |
| Asset turnover | – | – | – | – | 1.13 | 0.99 | 0.89 |
| Fixed asset turnover | – | – | – | – | 6.00 | 4.05 | 3.69 |
| Inventory turnover | – | – | – | – | 1.80 | 2.30 | 2.00 |
| Receivables turnover | – | – | – | – | 11.80 | 7.50 | 6.10 |
| Gross margin | – | – | – | – | 68.3% | 67.2% | 64.4% |
| Cash from operations to profit | – | – | – | 126.0% | – | 42.0% | 49.0% |
| Effective tax rate | 28.2% | 20.4% | 25.3% | 29.6% | 25.6% | 21.3% | 25.3% |
Outcome of Board Meeting held on October 29, 2026.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and any other applicable provisions, please note the schedule of earnings call below, for the quarter and half year ended September 30, 2026
Update on share purchase agreement dated July 29, 2026, with Actis Generics Private Limited
Significant increase in volume has been observed in RPG Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written…
Significant increase in volume has been observed in RPG Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written…
Schedule of meet
Update on completion of BTA execution by RPG Active Pharma Limited with Raghava Life Sciences Private Limited
Update on Investment and Shareholders Agreement entered on July 29, 2026, subsidiary of the Company allotted securities to the Investors.